(a)
| n | Cycles (n) | PR n (%) | SD n (%) | PD n (%) | ORR n (%) | |
|---|---|---|---|---|---|---|
| DAC | 8 | 2 | 0 (0) | 4 (50) | 4 (50) | 4 (50) |
| 3 | 4 | 0 (0) | 1 (33.33) | 2 (66.67) | 1 (33.33) | |
| 3* | 6 | 1 (50) | 0 (0) | 1 (50) | 1 (50) | |
|
| ||||||
| DAC + chemo | 18 | 2 | 1 (5.6) | 12 (66.7) | 5 (27.8) | 13 (72.3) |
| 11 | 4 | 2 (18.2) | 4 (36.4) | 5 (45.5) | 6 (54.5) | |
| 11 | 6 | 2 (18.2) | 5 (45.5) | 4 (36.4) | 7 (63.6) | |
|
| ||||||
| DAC + CIK | 5 | 2 | 0 (0) | 4 (80) | 1 (20) | 4 (80) |
| 5 | 4 | 0 (0) | 4 (80) | 1 (20) | 4 (80) | |
| 5 | 6 | 0 (0) | 4 (80) | 1 (20) | 4 (80) | |
Note. Data is n (%). CIK: cytokine induced killer cells; DAC + chemo: decitabine in combination with chemotherapy; DAC + CIK: decitabine in combination with CIK; PR: partial response; SD: stable disease; PD: progressive disease; ORR: objective response rate. Tumors were assessed every 2 cycles by using RECIST 1.0; RECIST: the Response Evaluation Criteria in Solid Tumors; *one patient discontinued treatment attributable to digestive tract hemorrhage.